Astressin B is a peptide that acts as a specific antagonist of corticotropin-releasing factor (CRF), which is a part of the hypothalamic-pituitary-adrenal (HPA) axis involved in stress responses. This peptide has been studied for its role in modulating stress, anxiety, and related behaviors, as well as its potential therapeutic effects in conditions associated with excessive CRF signaling.

While the function response did not provide specific details about dosing regimens for astressin B, it is generally understood that dosing can vary based on the context of the research or treatment application. In laboratory studies, dosing regimens may be defined based on factors like animal models, delivery methods (e.g., intravenous or subcutaneous), and specific research objectives. For clinical use, further investigations would be required to establish standard dosing protocols to ensure safety and efficacy in humans.

For precise dosing information, consulting specific clinical studies or authoritative medical sources is recommended. If you need detailed dosing guidelines or have a specific context in mind (like a clinical trial), please let me know!